Detail akcie Selvita online

Business Summary: Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Ryvu Therapeutics SA revenues increased 68% to PLN21.6M. Net loss increased 10% to PLN19.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects External services increase of 81% to PLN19.9M (expense), Employee benefit expense increase of 36% to PLN17.9M (expense).